Biogen Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.27B | $11.45B | $10.76B | $9.70B | $6.93B | $5.52B | $5.05B | $4.72B |
| TECFIDERA | $4.21B | $3.97B | — | — | — | — | — | — |
| Interferon (AVONEX+PLEGRIDY combined) | $2.65B | $2.80B | — | — | — | — | — | — |
| AVONEX | — | — | — | — | — | — | — | — |
| PLEGRIDY | — | — | — | — | — | — | — | — |
| TYSABRI | $1.97B | $1.96B | — | — | — | — | — | — |
| FAMPYRA | $91.6M | $84.9M | — | — | — | — | — | — |
| ZINBRYTA | $52.7M | $7.8M | — | — | — | — | — | — |
| VUMERITY | — | — | — | — | — | — | — | — |
| ELOCTATE | $48.4M | $513.2M | — | — | — | — | — | — |
| ALPROLIX | $26.0M | $333.7M | — | — | — | — | — | — |
| FUMADERM | $39.6M | $45.9M | — | — | — | — | — | — |
| SPINRAZA | $883.7M | $4.6M | — | — | — | — | — | — |
| ADUHELM | — | — | — | — | — | — | — | — |
| BENEPALI | $370.8M | $100.6M | — | — | — | — | — | — |
| IMRALDI | — | — | — | — | — | — | — | — |
| FLIXABI | $9.0M | $100.0K | — | — | — | — | — | — |
| BYOOVIZ | — | — | — | — | — | — | — | — |
| TOFIDENCE | — | — | — | — | — | — | — | — |
| QALSODY | — | — | — | — | — | — | — | — |
| SKYCLARYS | — | — | — | — | — | — | — | — |
| ZURZUVAE | — | — | — | — | — | — | — | — |
| FUMADERM and ADUHELM (combined) | — | — | — | — | — | — | — | — |
| Other Product Revenue | — | — | — | — | — | — | — | — |
| Revenue from anti-CD20 therapeutic programs | $1.56B | $1.31B | — | — | — | — | — | — |
| Alzheimer's collaboration revenue | — | — | — | — | — | — | — | — |
| Contract manufacturing, royalty and other revenue | $360.0M | $316.4M | — | — | — | — | — | — |
| Cost of Revenue | $1.63B | $1.48B | $1.24B | $1.17B | $857.7M | $545.5M | $466.8M | $400.3M |
| Gross Profit | $10.64B | $9.97B | $9.52B | $8.53B | $6.07B | $4.97B | $4.58B | $4.32B |
| Gross Margin | 86.7% | 87.1% | 88.5% | 87.9% | 87.6% | 90.1% | 90.8% | 91.5% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | $1.33B | $1.22B | $1.25B |
| SG&A Expense | $1.93B | $1.95B | $2.11B | $2.23B | $1.71B | $1.28B | $1.06B | $1.03B |
| Operating Income | $5.35B | $5.15B | $4.89B | $3.97B | $2.52B | $1.86B | $1.72B | $1.25B |
| Operating Margin | 43.6% | 45.0% | 45.4% | 40.9% | 36.3% | 33.6% | 34.2% | 26.5% |
| Interest Expense | $250.8M | $260.0M | $95.5M | $29.5M | $31.9M | $36.5M | $33.0M | $36.1M |
| Pretax Income | $5.13B | $4.93B | $4.77B | $3.95B | $2.48B | $1.86B | $1.71B | $1.23B |
| Income Tax Expense | $2.46B | $1.24B | $1.16B | $989.9M | $601.0M | $470.6M | $444.5M | $331.3M |
| Net Income | $2.54B | $3.70B | $3.55B | $2.93B | $1.86B | $1.38B | $1.23B | $1.01B |
| Net Margin | 20.7% | 32.3% | 33.0% | 30.2% | 26.9% | 25.0% | 24.5% | 21.3% |
| EPS (Basic) | $11.94 | $16.96 | $15.38 | $12.42 | $7.86 | $5.80 | $5.09 | $3.98 |
| EPS (Diluted) | $11.92 | $16.93 | $15.34 | $12.37 | $7.81 | $5.76 | $5.04 | $3.94 |
| Shares Outstanding (Basic) | 212.6M | 218.4M | 230.7M | 236.4M | 236.9M | 237.9M | 242.4M | 252.3M |
| Shares Outstanding (Diluted) | 213.0M | 218.8M | 231.2M | 237.2M | 238.3M | 239.7M | 245.0M | 254.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |